Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma by Yoshida, N et al.
Interleukin-6, tumour necrosis factor a and interleukin-1b in
patients with renal cell carcinoma
N Yoshida
1, S Ikemoto*
,1, K Narita
1, K Sugimura
1, S Wada
1, R Yasumoto
1, T Kishimoto
1 and T Nakatani
1
1Department of Urology, Osaka City University Medical School 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan
As regulators of malignant cell behaviour and communication with stroma, cytokines have proved useful in understanding
cancer biology and developing novel therapies. In renal cell carcinoma, patients with inﬂammatory reactions are known to have
poor prognosis. In order to elucidate the relation between renal cell carcinoma and the host, serum levels of inﬂammatory
cytokines, interleukin-6, tumour necrosis factor a, interleukin-1b, were measured. One hundred and twenty-two patients with
renal cell carcinoma and 21 healthy control subjects were studied, and serum cytokine levels were measured using a highly
sensitive ELISA kit. As a result, in the control group, interleukin-6, tumour necrosis factor a and interleukin-1b levels were
1.79+2.03, 2.74+0.94 and 0.16+0.17 pg ml
71, respectively. In the renal cell carcinoma patients, they were 8.91+13.12,
8.44+4.15 and 0.53+0.57 pg ml
71, respectively, and signiﬁcantly higher. In the comparison of stage, interleukin-6 level was
signiﬁcantly higher in the stage IV group compared to the other stage groups including the control group, while tumour
necrosis factor a level was signiﬁcantly higher in each stage group compared to the control group. As for grade, interleukin-6
level was signiﬁcantly higher in the grade 3 group compared to the control, grade 1 and grade 2 groups, while tumour necrosis
factor a level was signiﬁcantly higher in each grade group compared to the control group. All cytokines had a positive
correlation with tumour size. In regard to the correlation with CRP, all cytokines had a positive correlation with CRP, while
interleukin-6 had a particularly strong correlation. In conclusion, interleukin-6 may be one of the factors for the poor prognosis
of patients with renal cell carcinoma. In addition, tumour necrosis factor a may be useful in the early diagnosis of renal cell
carcinoma and post-operative follow-up.
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Renal cell carcinoma (RCC) is the most common malignant
tumour of the kidney. As regulators of malignant cell behaviour
and interaction with the host, cytokines have proved useful in
understanding cancer biology and developing novel therapies.
Among these cytokines, interleukin-6 (IL-6) has been frequently
studied in renal cell carcinoma (RCC). Miki et al (1989) reported
that freshly isolated RCC tissues expressed mRNA of IL-6 and
secreted active IL-6, and that IL-6 antiserum speciﬁcally inhibited
in vitro tumour growth. Takenawa et al (1991) reported that
primary RCC tissues and RCC cell lines expressed mRNA of IL-6
and IL-6 receptors, and that patients with a high level expression
of IL-6 had signiﬁcantly greater incidences of lymph node metasta-
sis and a larger increase in serum c-reactive protein (CRP) than
those without it. In addition, fresh RCC cells and cell lines have
been reported to produce IL-6 (Blay et al, 1994; Chang et al,
1997). These results suggest that IL-6 acts as an autocrine growth
factor for RCC cells. Blay et al (1992) reported that serum IL-6
was detectable in 66 of 138 patients (48%), and that serum CRP
correlated with IL-6 levels. The interval between diagnosis of the
primary tumour and metastasis was shorter in patients with a
detectable serum IL-6 and/or serum CRP level 450 mg l
71, and
they concluded that serum IL-6 and CRP levels were adverse prog-
nosis factors in patients with metastatic renal cell carcinoma. They
also reported that the presence of high pretreatment serum IL-6
levels inversely correlated to the response to IL-2 and to survival
after immunotherapy with IL-2 in patients with RCC (Blay et al,
1990). Tsukamoto et al (1992) reported that serum IL-6 was
detected in 18 out of 71 patients (25%). They indicated that
although IL-6 level did not directly correlate with tumour volume
and differentiation grade of the carcinoma, the positive rate
increased with progression of the stage, and that serum IL-6 level
affected the 5-year survival of patients without distant metastasis.
Furthermore, Stadler et al (1992) and Dosquet et al (1994)
reported that serum IL-6 was a good marker for metastases in
RCC patients. However, as these studies did not use a high sensi-
tivity method, the obtained values were lower than the minimum
detectable levels in many of the patients. In this study, we used a
highly sensitive ELISA kit in order to study in more detail the
signiﬁcance of serum IL-6 in RCC patients.
Tumour necrosis factor a (TNFa) and interleukin-1b (IL-1b) are
pleiotropic mediators of biologic responses related to infection,
immunity, and inﬂammation (Le and Vilcek, 1987). IL-1, TNFa
and IL-6 are cytokines with overlapping biological properties which
form a complex network of interactive signals. They are considered
major mediators of fever and the production of acute phase
proteins (Baumann and Gauldie, 1990). There have been few
reports on serum TNF and serum IL-1 in RCC. In multivariate
analysis for proportional hazard regression, Dosquet et al (1997)
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www.bjcancer.comreported that TNFa was an independent prognostic indicator, with
a normal plasma TNFa being highly predictive for a good
prognosis in patients with untreated renal cell carcinoma.
Determining the levels of these cytokines in the serum may not
only help in understanding the biology of the tumour, but they
may also be useful as a diagnosis. In this study, we measured the
serum levels of the cytokines in RCC patients using a highly sensi-
tive ELISA kit and also investigated these cytokines in the
supernatant of short-term and long-term established RCC cells.
MATERIALS AND METHODS
Patients
One hundred and twenty-two patients with RCC (mean age: 62.4
years) were studied. Histological examination of their tumours
indicated RCC in all cases. Tumour stages were classiﬁed according
to Robson’s classiﬁcation. The patients were also divided into three
groups according to grade. They did not receive any treatment
before the admission to the study. Twenty-one healthy control
subjects (mean age:61.9 years) were also studied.
Assay of IL-6, TNFa and IL-1b in serum
Serum from the peripheral venous blood of the patients and
healthy control subjects was frozen at 7808C until use. Serum
cytokine levels were measured using a highly sensitive ELISA kit
(Genzyme Techne Analyza Immunoassay System human IL-6, TNFa,
IL-1b High Sensitivity). The minimum detectable concentrations
were estimated to be 0.094 pg ml
71 for IL-6, 0.18 pg ml
71 for TNFa
and 0.1 pg ml
71 for IL-1b.
Short-term and long-term established RCC lines
Tumour cells were isolated by enzymatic digestion of surgically
removed tumour tissues. Short-term cultured RCC were established
by culturing the tumour cell suspension in a 24-well plastic tissue
culture cluster (Corning Inc., NY, USA) in RPMI 1640 (Nikken
Bio Medical Laboratory, Japan) supplemented with 10% foetal calf
serum (FCS) (Equitech-BIO, Inc., Ingram, TX, USA). Cells were
grown for 2 weeks and then split by the use of tripsin. Tumour cells
that had been through 4 to 5 passages were characterised by immu-
nostaining with antibodies to RCC (Monosen, San Francisco, CA,
USA) and Uro2 (Signet, Dedham, MA, USA). In some of the
patients, long-term cell culture of 20 passages or more were possible.
Assay of IL-6, TNFa and IL-1b in cell culture supernatant
RCC lines (1610
5 cells ml
71) were cultured in RPMI 1640 supple-
mented with 10% FCS for 48 h. The supernatant was centifuged,
passed through a Millipore ﬁlter (0.45 m) and stored at 7808C
until testing. Cytokine levels were measured using an ELISA kit
(Genzyme Techne Analyza Immunoassay System human IL-6, TNFa,
IL-1b). The minimum detectable concentrations were estimated to
be 0.7 pg ml
71 for IL-6, 4.4 pg ml
71 for TNFa and 1.0 pg ml
71
for IL-1b.
Statistical analysis
The data are presented as mean+standard deviation. The data
were analysed by multiple comparison (Fisher’s PLSD) after one-
factor ANOVA. Regression lines were ﬁtted by the method of least
squares. Receiver operating characteristic (ROC) curves were
constructed for IL-6, TNFa and IL-1b by calculating their sensitiv-
ity and speciﬁcity in differentiating RCC patients from healthy
control subjects at several cutoffs.
RESULTS
Serum levels of IL-6, TNFa and IL-1b in the RCC patients and
healthy control subjects are summarised in Table 1. In the control
subjects, IL-6 level was 1.79+2.03 pg ml
71, TNFa level was
2.74+0.94 pg ml
71 and IL-1b level was 0.16+0.17 pg ml
71, while
in the RCC patients, IL-6 level was 8.91+13.12 pg ml
71, TNFa
level was 8.44+4.15 pg ml
71 and IL-1b level was
0.53+0.57 pg ml
71 and signiﬁcantly higher (IL-6: P50.05, TNFa:
P50.0001, IL-1b, P50.05). RCC patients were also divided
according to stage (I, II, III, IV), grade (G1, G2, G3) and with
or without lymph node or distal metastasis (metastasis, non-metas-
tasis). When compared according to stage, IL-6 level was
signiﬁcantly higher in the stage IV group compared to the other
stage groups including the control group, while TNFa level was
signiﬁcantly higher in each stage group compared to the control
group. There was no signiﬁcant difference in IL-1b level in among
the groups. When compared according to grade, IL-6 level was
signiﬁcantly higher in the G3 group compared to the control, G1
and G2 groups, while TNFa level was signiﬁcantly higher in each
grade group compared to the control group. IL-1b level was signif-
icantly higher in the G2 group compared to the control group. In
the comparison of with or without metastasis, IL-6, TNFa and IL-
1b levels were signiﬁcantly higher in the metastasis group
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Table 1 Serum cytokine levels in relation to tumour stage, grade and metastasis in 124 patients with RCC
IL-6 (pg ml
71) TNFa (pg ml
71) IL-1b (pg ml
71)
Mean+s.d. Median (range) P value Mean+s.d. Median (range) P value Mean+s.d. Median (range) P value
Control subjects 1.79+2.03 1.0 (0.2–7.8) 2.74+0.94 2.7 (1.0–4.7) 0.16+0.17 0.08 (0–0.61)
RCC patients 8.91+13.12 2.9 (0.2–62.4) 8.44+4.15 7.1 (1.0–23.4) 0.53+0.57 0.2 (0–4.5)
Stage C C C
Stage I 4.81+6.44 2.8 (0.4–34.8) NS I 7.50+3.22 7.2 (1.5–23.4) *** I 0.51+0.91 0.18 (0–4.5 NS I
Stage II 3.36+3.24 1.9 (1.2–12.6) NS NS II 7.75+2.55 8.2 (1.4–10.7) *** NS II 0.53+0.75 0.15 (0–2.4) NS NS II
Stage III 9.61+13.2 3.6 (1.0–46.5) * NS NS III 7.99+3.75 7.5 (2.4–16.5) *** NS NS III 0.53+0.63 0.2 (0–1.8) NS NS NS III
Stage IV 21.8+20.9 9.4 (1.0–62.4) *** *** *** ** IV 9.40+4.92 8.7 (1.6–19.2) *** * NS NS IV 0.59+0.51 0.55 (0–1.5) NS NS NS NS IV
Grade C C C
G1 3.94+4.64 2.6 (0.8–20.1) NS G1 6.46+6.13 6.3 (1.4–11.5) *** G1 0.51+0.77 0.14 (0–3.3) NS G1
G2 6.32+9.76 2.4 (0.4–50) NS NS G2 7.85+7.05 8.2 (1.5–13.9) ** * G2 0.60+0.89 0.25 (0–4.5) * NS GS
G3 13.7+17.1 5.3 (1.5–47.3) ** * * G3 8.38+14.5 8.4 (3.0–16.5) *** * NS G3 0.28+0.390 0.11 (0–1.1) NS NS NS G3
Metastasis C C C
Non-metastasis 6.83+10.2 1.8 (0.2–34.8) NS NM 7.94+4.09 7.5 (1.4–21.5) *** NM 0.57+0.89 0.2 (0–4.5) * NM
Metastasis 22.7+20.9 3.7 (1.0–62.4) *** *** M 9.85+4.71 9.75 (1.6–23.4) *** * M 0.69+0.54 0.65 (0–1.6) * NS M
Values are expressed as mean+s.d., median and range. *P50.05, **P50.01, ***P50.001.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1396–1400compared to the control and non-metastasis groups. TNFa level
was also signiﬁcantly higher in the non-metastasis group compared
to the control group (Table 1).
There was a positive correlation between tumour size and IL-6,
TNFa and IL-1b levels (IL-6: r=0.42, P50.0001; TNFa: r=0.31,
P50.001; IL-1b: r=0.41, P50.005) (Figure 1). There was also a
positive correlation between CRP and IL-6 and TNFa levels (IL-
6: r=0.83, P50.0001; TNFa: r=0.43, P50.0001) (Figure 2).
The ROC curve analysis was used for the comparison of cyto-
kine levels in the evaluation of RCC diagnosis. In this analysis,
area under the curve (AUC) of serum TNFa was best compared
to the other cytokines (Figure 3).
Cytokine levels of the culture supernatants of short-term and
long-term established RCC lines are shown in Tables 2 and 3.
IL-6 level was high in all patients, and while TNFa and IL-1b levels
could be detected in some of the cells, these levels were low in all
cases and under minimum detectable concentrations in most cases.
IL-6 tended to be lower in the long-term established RCC lines
compared to the short-term established RCC lines.
DISCUSSION
IL-6 is a pleiotropic cytokine secreted by a wide variety of cell types
including lymphocytes, monocytes and tumour cells (Le and
Vilcek, 1989; Kishimoto et al, 1992). There have been several
reports that RCC can produce IL-6 and act as an autocrine growth
factor (Blay et al, 1994; Chang et al, 1997). In our study of RCC
using short-term and long-term established cell culture, IL-6 was
also produced at high levels. These observations support the
hypothesis that IL-6 may be a marker of tumour aggressiveness.
Blay et al (1992) reported that serum IL-6 was positive in 48%
of patients with RCC. Tsukamoto et al (1992) reported that it
was positive in 25% and Hamao et al (1994) reported that it
was positive in 53%. In our study, serum IL-6 could be detected
in all patients in the control group and RCC group by using a
highly sensitive ELISA kit in our present study. Tsukamoto et al
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Figure 1 Correlation between serum concentrations of cytokines and tumour size in patients with RCC.
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Figure 2 Correlation between serum concentrations of cytokines and CRP in patients with RCC.
Table 2 Cytokine levels of short-term established RCC lines culture
supernatant
Pt. Age IL-6 TNFa IL-1b
No (years) Sex Stage Grade (pg ml
71) (pg ml
71) (pg ml
71)
1 71 M VI G3 20580 0 10
2 62 M I G2 25240 32 0
3 71 F I G1 11320 11 0
4 24 F I G2 21500 0 9
5 51 F I G1 13720 0 0
6 58 F II G2 7280 0 0
7 62 M III G2 23160 14 0
8 60 M I G2 13520 8 0
9 70 M I G2 1200 0 0
10 60 M I G1 15230 7 0
11 67 M III G2 8970 0 0
12 62 M IV G2 11680 0 0
13 69 M I G1 19530 0 0
14 52 M II G2 18000 5 0
15 58 M I G1 1280 0 0
16 71 M III G2 10680 0 0
17 63 M III G3 18280 6 0
18 45 M I G1 10900 0 0
19 71 M III G2 12420 0 0
20 69 M II G2 6840 0 7
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IL-6 positive patients increased with stage, and Dosquet et al
(1994) reported the IL-6 blood levels were higher in patients with
lymph node invasion and/or distant metastases. In our study,
serum IL-6 level was signiﬁcantly higher in the stage IV group
compared to the control, stage I, stage II and stage III groups.
Tsukamoto et al (1992) reported that there was no correlation of
serum IL-6 with grade and tumour size, while Dosquet et al
(1994) also reported that there was no correlation with tumour
size. In another report, a correlation between serum IL-6 and
tumour size was indicated in ovarian cancer (Berek et al, 1991).
In our study, IL-6 was signiﬁcantly higher in the grade 3 group
compared to the grade 1 and grade 2 groups, and there was a posi-
tive correlation with tumour size. These results can be attributed to
our use of the high sensitivity method. IL-6 exerts pyrogenic activ-
ity and induces the production of acute-phase proteins including
CRP and haptoglobulin by liver cells in vitro. Blay et al (1992)
and Dosquet et al (1994) reported that there was a positive correla-
tion between serum IL-6 and CRP, we similarly found a positive
correlation between serum IL-6, TNFa and IL-1b and CRP, but
IL-6 had the strongest correlation.
TNFa is recognised as a potentially powerful immune mediator
and multifunctional cytokine that regulates the central aspects of
host defence responses and plays a major role in the pathogenesis
of various immune disorders such as fever, septic shock, arthritis
and inﬂammatory reaction (Brenner, 1988; Frei and Spriggs,
1989). IL-1b is involved in many host reactions including immu-
nologic, inﬂammatory, endocrinologic and haemopoietic ones.
Furthermore, IL-1b performs a synergistic role in potentiating
natural killer cell and macrophage-mediated tumour lysis (Dinarel-
lo, 1989; Platanias and Vogelzang, 1990). TNFa and IL-1b are
cytokines with overlapping biological properties which form a
complex network of interactive signals (Le and Vilcek, 1987) and
are produced mainly by cells of the monocytes–macrophage series
(Nathan, 1987). It has been reported that TNFa is produced from
RCC cells (Gogusev et al, 1993), but Waase et al (1992) reported
that mRNA of TNF was expressed in inﬁltrating monocytes–
macrophages in RCC but never by the tumour cells, and that the
degree of TNF-a production in RCC depends on tumour spread
to the draining lymph nodes. In our study, when the levels in
the culture supernatant of short-term and long-term established
cells were measured, TNFa and IL-1b levels were lower than the
minimum detectable concentrations in many cases, suggesting that
they are mainly produced by monocytes–macrophages. There are
very few studies on serum TNFa and IL-1b in RCC patients. Bich-
ler et al (1990) reported that when serum TNFa level was measured
in 29 RCC patients, patients with metastatic disease could exhibit
increased levels of serum TNF and that the decrease in TNF may
be associated with a better prognosis.
Dosquet et al (1997) reported that plasma TNFa level was
higher in RCC patients compared to healthy controls, and that
it was higher in the disseminated group compared to the undis-
seminated group. They also reported that in multivariate analysis
for proportional hazard regression, only TNFa was an indepen-
dent prognostic indicator, with a normal plasma TNFa being
highly predictive for a good prognosis in patients with RCC
(Dosquet et al, 1997). Hamao et al (1994) reported that serum
TNFa was elevated in 6 out of 32 patients (18.8%) and serum
IL-1 was elevated in 1 out of 32 patients (3.1%). They also
reported that the number of serum TNFa-positive patients
increased with stage. In this study, we were able to measure
serum TNFa and serum IL-1b levels in all the control subjects
and RCC patients by using a highly sensitive ELISA kit. Serum
TNFa level was signiﬁcantly higher in the stage I, II, III and
IV groups compared to the control group, and unlike serum
IL-6, it was already increased in the low stage. There was no
signiﬁcant difference in serum IL-1b level among the groups.
As for grade, it was higher in the grade 1, 2 and 3 groups
compared to the control group, and unlike serum IL-6, it was
already increased in grade 1. In the ROC curve analysis, AUC
of serum TNFa was best compared to other cytokines. These
results indicate that the production of IL-6 in RCC patients is
related to parameters of tumour progression such as tumour size
and the existence of metastasis. As for TNFa, it was already
higher in the stage I group and grade 1 group compared to
the control group, so that it may be useful in early diagnosis
and post-operative follow-up. TNFa has been directly shown to
serve as anticancer bioactive molecules. In addition, TNFa indir-
ectly exerts antitumour effects by activation of T cells, NK cells
and macrophages. The increased TNFa secretion in RCC patients
may be considered as a favourable compensatory mechanism to
counteract tumour growth. However, TNFa mediates the catabo-
lism of the body substrate. The increased TNFa secretion may
induce a hypermetabolic status that may be a cause of malnutri-
tion and cancer cachexia. Further studies on the role of these
cytokines in tumour progression should provide some insight
into RCC treatment.
REFERENCES
Baumann H, Gauldie J (1990) Regulation of hepatic acute phase protein
genes by hepatocyte stimulating factors and other mediators of inﬂamma-
tion. Mol Biol Med 7: 147–159
Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O (1991)
Serum interleukin-6 levels correlate with disease status in patients with
epithelial ovarian cancer. Am J Obstet Gynecol 164: 1038–1043
Bichler KH, Kleinknecht S, Strohmeier WL (1990) Immune status and
immune therapy of renal cell carcinoma. Urol Int 45: 269–283
Blay JY, Favrot M, Negrier S, Combaret V, Chouaib S, Mercatello A, Kaem-
merlen P, Franks CR, Phillips T (1990) Correlation between clinical
response to interleukin 2 therapy and sustained production of tumor
necrosis factor. Cancer Res 50: 2371–2374
C
l
i
n
i
c
a
l
1
0.8
0.6
0.4
0.2
0
S
e
n
s
i
t
i
v
i
t
y
0             0.2           0.4           0.6            0.8            1
1-Specificity
IL-6
TNFa
IL-1b
Figure 3 ROC curve of cytokines in healthy control subjects and
patients with RCC.
Table 3 Cytokine levels of long-term established RCC lines culture
supernatant
Pt. Age IL-6 TNFa IL-1b
no. (years) Sex Stage Grade (pg ml
71) (pg ml
71) (pg ml
71)
1 58 M II G2 8060 39 0
2 71 F I G1 940 0 0
3 62 M I G1 2290 0 37
4 70 M I G2 1230 0 0
5 67 M V G2 2650 0 0
Inflammatory cytokines in renal cell carcinoma
N Yoshida et al
1399
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1396–1400Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Revault
AMA, Tourani JM, Moskovtchenko JF, Philip T, Favrot M (1992) Serum
level of interleukin 6 as a prognosis factor in metastatic renal cell carcino-
ma. Cancer Res 52: 3317–3322
Blay JY, Schemann S, Favrot M (1994) Local production of interleukin-6 by
renal adenocarcinoma in vivo. J Natl Cancer Inst 86: 238–239
Brenner MK (1988) Tumor necrosis factor. Br J Haematol 69: 149–152
Chang SG, Lee SJ, Lee SJ, Kim JI, Jung JC, Kim JH, Hoffman RM (1997)
Interleukin-6 production in primary histoculture by normal human kidney
and renal tumor tissues. Anticancer Res 17: 113–116
Dinarello CA (1989) Interleukin-1 and biologically related cytokines. Adv
Immunol 44: 153–205
Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F (1997) Are angio-
genic factors, cytokines, and soluble adhesion molecules prognostic
factors in patients with renal cell carcinoma? Clin Cancer Res 3: 2451–2458
Dosquet C, Schaetz A, Faucher C, Lepag E, Wautier JL, Richard F, Cabane J
(1994) Tumor necrosis factor-a, interleukin-1b and interleukin-6 in
patients with renal cell carcinoma. Eur J Cancer 30A: 162–167
Frei E, Spriggs D (1989) Tumor necrosis factor: still a promising agent. J Clin
Oncol 7: 291–294
Gogusev J, August M, Chretien Y, Droz D (1993) Interleukin-6 and TNFa
production in human renal cell carcinoma. Kidney Int 44: 585–592
Hamao T, Kanayama H, Kan M, Takigawa H, Kagawa S (1994) Serum level
and gene expression of interleukin-1 beta, interleukin-6 and tumor necro-
sis factor-alpha in human renal cell carcinoma. Nippon Hinyoukika Gakkai
Zasshi 85: 563–570
Kishimoto T, Akira A, Taga T (1992) Interleukin-6 and its receptor: a para-
digm for cytokines. Science 258: 593–597
Le J, Vilcek IC (1987) Tumor necrosis factor and interleukin-1: cytokines
with multiple overlapping biologic activities. Lab Invest 56: 234–248
Le J, Vilcek IC (1989) Biology of disease. Interleukin-6: multifunctional cyto-
kine regulating immune reaction and the acute phase protein response. Lab
Invest 61: 588–602
Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T,
Hirano T, Kishimoto T (1989) Interleukin-6 functions as an in vitro auto-
crine growth factor in renal cell carcinomas. FEBS Lett 250: 607–610
Nathan CF (1987) Secretary products of macrophages. J Clin Invest 79: 310–
326
Platanias LC, Vogelzang NJ (1990) Interleukin-1: biology, pathophysiology,
and clinical prospects. Am J Med 89: 621–628
Stadler WM, Richards JM, Vogelzang NJ (1992) Serum interleukin-6 levels in
metastatic renal cell cancer: correlation with survival but not an indepen-
dent prognostic indicator. J Natl Cancer Inst 84: 1835–1836
Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H,
Nakayama H, Fujita J, Yoshida O (1991) Enhanced expression of interleu-
kin-6 in primary human renal call carcinoma. J Natl Cancer Inst 83: 1668–
1672
Tsukamoto T, Kumamoto Y, Miyao N, Masumori N, Takahashi A, Yanase M
(1992) Interleukin-6 in renal cell carcinoma. J Urol 148: 1778–1782
Waase I, Bergholz M, Iglauer A, Beissert S, Blech M, Schauer A, Kronke M
(1992) Heterogeneity of tumor necrosis factor production in renal cell
carcinoma. Eur J Cancer 28A: 1660–1664
C
l
i
n
i
c
a
l
Inflammatory cytokines in renal cell carcinoma
N Yoshida et al
1400
British Journal of Cancer (2002) 86(9), 1396–1400 ã 2002 Cancer Research UK